ENDOKRYNOL POL 润色咨询

Endokrynologia Polska

出版年份：1950 年文章数：622 投稿命中率： 开通期刊会员，数据随心看

出版周期：Bimonthly 自引率：12.6% 审稿周期： 开通期刊会员，数据随心看

前往期刊查询
期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=2122237, encodeId=5c2c212223e9c, content=审稿速度:2.0 | 投稿命中率:50.0<br>经验分享：2022年9月底投稿，一审两个月直接接收，没有大小修，国人占比还行，拒稿也很快，可以尝试, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b7c8276801, createdName=ms9000001512945810, createdTime=Tue Mar 28 10:39:25 CST 2023, time=2023-03-28, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2165787, encodeId=38b92165e87be, content=审稿速度:1.0 | 投稿命中率:75.0<br>偏重的研究方向：视网膜;糖网;临床<br>经验分享：2023.7.1投稿，7.31通知返修，内容基本未做修改，回答了审稿人问题，8.10修回，8.16日接收，10.11日proof,10.23日publish, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7421602609, createdName=xiaominer1987, createdTime=Mon Oct 30 20:09:41 CST 2023, time=2023-10-30, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2165786, encodeId=6d672165e8629, content=审稿速度:1.0 | 投稿命中率:75.0<br>偏重的研究方向：视网膜;糖尿病视网膜病变<br>经验分享：2023.7.1投稿，7.3 in reverw,7.31通知返修, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7421602609, createdName=xiaominer1987, createdTime=Mon Oct 30 20:06:57 CST 2023, time=2023-10-30, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=1101549, encodeId=882a110154968, content=审稿人怎么利用关键词审稿？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Wed Dec 29 14:52:51 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1101550, encodeId=91c01101550ff, content=引言怎么写？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Tue Dec 28 14:52:51 CST 2021, time=2021-12-28, status=1, ipAttribution=)]
    2023-03-28 ms9000001512945810 来自浙江省

    审稿速度:2.0 | 投稿命中率:50.0
    经验分享：2022年9月底投稿，一审两个月直接接收，没有大小修，国人占比还行，拒稿也很快，可以尝试

    3

    展开3条回复
  2. [GetPortalCommentsPageByObjectIdResponse(id=2122237, encodeId=5c2c212223e9c, content=审稿速度:2.0 | 投稿命中率:50.0<br>经验分享：2022年9月底投稿，一审两个月直接接收，没有大小修，国人占比还行，拒稿也很快，可以尝试, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b7c8276801, createdName=ms9000001512945810, createdTime=Tue Mar 28 10:39:25 CST 2023, time=2023-03-28, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2165787, encodeId=38b92165e87be, content=审稿速度:1.0 | 投稿命中率:75.0<br>偏重的研究方向：视网膜;糖网;临床<br>经验分享：2023.7.1投稿，7.31通知返修，内容基本未做修改，回答了审稿人问题，8.10修回，8.16日接收，10.11日proof,10.23日publish, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7421602609, createdName=xiaominer1987, createdTime=Mon Oct 30 20:09:41 CST 2023, time=2023-10-30, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2165786, encodeId=6d672165e8629, content=审稿速度:1.0 | 投稿命中率:75.0<br>偏重的研究方向：视网膜;糖尿病视网膜病变<br>经验分享：2023.7.1投稿，7.3 in reverw,7.31通知返修, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7421602609, createdName=xiaominer1987, createdTime=Mon Oct 30 20:06:57 CST 2023, time=2023-10-30, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=1101549, encodeId=882a110154968, content=审稿人怎么利用关键词审稿？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Wed Dec 29 14:52:51 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1101550, encodeId=91c01101550ff, content=引言怎么写？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Tue Dec 28 14:52:51 CST 2021, time=2021-12-28, status=1, ipAttribution=)]
    2023-10-30 xiaominer1987 来自河北省

    审稿速度:1.0 | 投稿命中率:75.0
    偏重的研究方向：视网膜;糖网;临床
    经验分享：2023.7.1投稿，7.31通知返修，内容基本未做修改，回答了审稿人问题，8.10修回，8.16日接收，10.11日proof,10.23日publish

    2

    展开2条回复
  3. [GetPortalCommentsPageByObjectIdResponse(id=2122237, encodeId=5c2c212223e9c, content=审稿速度:2.0 | 投稿命中率:50.0<br>经验分享：2022年9月底投稿，一审两个月直接接收，没有大小修，国人占比还行，拒稿也很快，可以尝试, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b7c8276801, createdName=ms9000001512945810, createdTime=Tue Mar 28 10:39:25 CST 2023, time=2023-03-28, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2165787, encodeId=38b92165e87be, content=审稿速度:1.0 | 投稿命中率:75.0<br>偏重的研究方向：视网膜;糖网;临床<br>经验分享：2023.7.1投稿，7.31通知返修，内容基本未做修改，回答了审稿人问题，8.10修回，8.16日接收，10.11日proof,10.23日publish, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7421602609, createdName=xiaominer1987, createdTime=Mon Oct 30 20:09:41 CST 2023, time=2023-10-30, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2165786, encodeId=6d672165e8629, content=审稿速度:1.0 | 投稿命中率:75.0<br>偏重的研究方向：视网膜;糖尿病视网膜病变<br>经验分享：2023.7.1投稿，7.3 in reverw,7.31通知返修, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7421602609, createdName=xiaominer1987, createdTime=Mon Oct 30 20:06:57 CST 2023, time=2023-10-30, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=1101549, encodeId=882a110154968, content=审稿人怎么利用关键词审稿？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Wed Dec 29 14:52:51 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1101550, encodeId=91c01101550ff, content=引言怎么写？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Tue Dec 28 14:52:51 CST 2021, time=2021-12-28, status=1, ipAttribution=)]
    2023-10-30 xiaominer1987 来自河北省

    审稿速度:1.0 | 投稿命中率:75.0
    偏重的研究方向：视网膜;糖尿病视网膜病变
    经验分享：2023.7.1投稿，7.3 in reverw,7.31通知返修

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2122237, encodeId=5c2c212223e9c, content=审稿速度:2.0 | 投稿命中率:50.0<br>经验分享：2022年9月底投稿，一审两个月直接接收，没有大小修，国人占比还行，拒稿也很快，可以尝试, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b7c8276801, createdName=ms9000001512945810, createdTime=Tue Mar 28 10:39:25 CST 2023, time=2023-03-28, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2165787, encodeId=38b92165e87be, content=审稿速度:1.0 | 投稿命中率:75.0<br>偏重的研究方向：视网膜;糖网;临床<br>经验分享：2023.7.1投稿，7.31通知返修，内容基本未做修改，回答了审稿人问题，8.10修回，8.16日接收，10.11日proof,10.23日publish, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7421602609, createdName=xiaominer1987, createdTime=Mon Oct 30 20:09:41 CST 2023, time=2023-10-30, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2165786, encodeId=6d672165e8629, content=审稿速度:1.0 | 投稿命中率:75.0<br>偏重的研究方向：视网膜;糖尿病视网膜病变<br>经验分享：2023.7.1投稿，7.3 in reverw,7.31通知返修, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7421602609, createdName=xiaominer1987, createdTime=Mon Oct 30 20:06:57 CST 2023, time=2023-10-30, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=1101549, encodeId=882a110154968, content=审稿人怎么利用关键词审稿？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Wed Dec 29 14:52:51 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1101550, encodeId=91c01101550ff, content=引言怎么写？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Tue Dec 28 14:52:51 CST 2021, time=2021-12-28, status=1, ipAttribution=)]
    2021-12-29 小动量

    审稿人怎么利用关键词审稿？

    1

    展开1条回复
  5. [GetPortalCommentsPageByObjectIdResponse(id=2122237, encodeId=5c2c212223e9c, content=审稿速度:2.0 | 投稿命中率:50.0<br>经验分享：2022年9月底投稿，一审两个月直接接收，没有大小修，国人占比还行，拒稿也很快，可以尝试, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b7c8276801, createdName=ms9000001512945810, createdTime=Tue Mar 28 10:39:25 CST 2023, time=2023-03-28, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2165787, encodeId=38b92165e87be, content=审稿速度:1.0 | 投稿命中率:75.0<br>偏重的研究方向：视网膜;糖网;临床<br>经验分享：2023.7.1投稿，7.31通知返修，内容基本未做修改，回答了审稿人问题，8.10修回，8.16日接收，10.11日proof,10.23日publish, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7421602609, createdName=xiaominer1987, createdTime=Mon Oct 30 20:09:41 CST 2023, time=2023-10-30, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2165786, encodeId=6d672165e8629, content=审稿速度:1.0 | 投稿命中率:75.0<br>偏重的研究方向：视网膜;糖尿病视网膜病变<br>经验分享：2023.7.1投稿，7.3 in reverw,7.31通知返修, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7421602609, createdName=xiaominer1987, createdTime=Mon Oct 30 20:06:57 CST 2023, time=2023-10-30, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=1101549, encodeId=882a110154968, content=审稿人怎么利用关键词审稿？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Wed Dec 29 14:52:51 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1101550, encodeId=91c01101550ff, content=引言怎么写？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Tue Dec 28 14:52:51 CST 2021, time=2021-12-28, status=1, ipAttribution=)]
    2021-12-28 桑晒麦拉

    引言怎么写？

    1

    展开1条回复
共12条页码: 1/2页10条/页
分享您的投稿经验，提升MI经验值，获取更多积分